Use of lorazepam and survival outcomes for patients with pancreatic cancer

A retrospective study investigating the impact of palliative care medicine on the tumor microenvironment has found that patients with pancreatic cancer who were prescribed the benzodiazepine lorazepam while undergoing chemotherapy had shorter progression-free survival than those patients who did not receive the benzodiazepine.